[Treatment of dyslipoproteinemia by systemic enzyme therapy in experimental glomerulonephritis].
Patients with chronic glomerulonephritis (CG) develop disturbances of lipid blood spectrum leading to additional damage to renal structure. The existent methods of pathogenetic therapy have no effect on lipid imbalance. Recently, many autoimmune diseases have been treated with systemic enzyme therapy (SET). The authors studied SET effect in disturbed lipid metabolism in experimental glomerulonephritis. Experimental animals showed morphological and biochemical changes similar to those in CG of man. SET reduced renal tissue damage and symptoms of dyslipoproteinemia.
Mukhin
I V
IV
D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000284:Administration, Oral; D000818:Animals; D001327:Autoimmune Diseases / Q000150:complications / Q000473:pathology; D003520:Cyclophosphamide / Q000627:therapeutic use; D004195:Disease Models, Animal; D004338:Drug Combinations; D005921:Glomerulonephritis / Q000150:complications* / Q000473:pathology; D006867:Hydrolases / Q000627:therapeutic use*; D006951:Hyperlipoproteinemias / Q000188:drug therapy* / Q000209:etiology / Q000473:pathology; D007273:Injections, Intramuscular; D007668:Kidney / Q000187:drug effects* / Q000473:pathology; D008297:Male; D011239:Prednisolone / Q000627:therapeutic use; D051381:Rats; D012431:Rutin / Q000627:therapeutic use*
D000276:Adjuvants, Immunologic; D004338:Drug Combinations; D012431:Rutin; C023295:Wobenzym; D003520:Cyclophosphamide; D011239:Prednisolone; D006867:Hydrolases